PATENT CLAIM ANALYSIS

Application Number: 16050102
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "004800"]

Abstract:
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Claim (Index 9):
An amylin analogue according to  claim 1  wherein Z is an amino acid sequence of formula II: (II) (SEQ\u2003ID\u2003NO:\u20034)\u2003 X1-X2-Gly-Thr-Ala-Thr-X7-Ala-Thr-X10-Arg-Leu-Ala- X14-Phe-Leu-Gln-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile (Me)-X27-Ser-Ser-Thr-Glu-Val-Gly-Ser-Asn-Thr-Hyp wherein X1 is selected from Arg and Lys; X10 is selected from the group consisting of Glu and Gln; X14 is selected from the group consisting of Aad, Asp and His; X19-X20 is selected from Ser-Ser and Thr-Thr or is absent; X27 is selected from the group consisting of Leu and Pro; and X2 and X7 are amino acid residues whose side chains together form a lactam bridge.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.4898
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15698743', '14398260', '11278014', '14800627', '15442229']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8133921829728684
- 35 USC 102 Novelty (BERT): 0.7354129080950315
- Combined Prediction Score: 0.8055942554850847
- Mean Citation Score: 487.11570200000006
- Max Citation Score: 847.1067
- Similarity Product: 805.3809838311374

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test